Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report.
Background
Buprenorphine is a partial mu-opioid receptor agonist approved for the treatment of opioid dependence. The risk of withdrawal symptoms and wait time required to safely initiate buprenorphine provides challenges to both patients and providers. Microdose induction is proposed as a possible solution to ease the transition to buprenorphine; however, little data has been published to date on patients stabilized on methadone doses greater than 100 mg.


Case Report
A 29-year-old patient stabilized on methadone 105 mg was successfully transitioned to sublingual buprenorphine-naloxone using a 7-day microdose protocol on an inpatient psychiatric service. During the transition, the patient reported only minimal symptoms.


Conclusion
This report adds to the growing literature supporting the use of a microdose induction to initiate buprenorphine-naloxone. Additionally, this approach may be significant for patients stabilized on high doses of methadone who may not be able to tolerate a traditional buprenorphine induction.
['Menard|Shannon|S|https://orcid.org/0000-0002-2735-9692', 'Jhawar|Archana|A|https://orcid.org/0000-0003-2317-5586']
microdose methadone buprenorphine OUD SUD opioid use disorder substance use disorder